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Key content
 Twin pregnancies are associated with a three-fold greater
perinatal mortality than singleton pregnancies. Prematurity is a
main contributor, with 50% of twin pregnancies delivering
before 37 weeks and 10% delivering before 32 weeks
of gestation.
 The aetiology of preterm delivery in twin pregnancies is likely
multifactorial and different from that of singletons.
 Cervical cerclage reduces preterm birth rates in singletons but has
mixed results in twins with some studies showing harm.
 The use of progesterone to prevent preterm birth in singletons has
conflicting results and has not been proven to prevent preterm
birth in twins. Studies continue to determine whether the cervical
pessary is effective in preventing preterm birth in
multiple pregnancies.
 There is a paucity of data available on the prevention of preterm
birth in triplets/higher order multiples but similar principles to
twin pregnancy apply.
Learning objectives
 To review the burden of preterm birth in multiple pregnancy.
 To understand the methods available for preventing preterm birth in
multiplepregnancies and the evidence surrounding theuseof eachone.
 To be aware of the use of the Arabin pessary.
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Introduction
Twin pregnancies are high-risk and associated with increased
perinatal morbidity and mortality.1 Multiple pregnancy is
associated with adverse maternal outcomes including
increased rates of pre-eclampsia, pregnancy-induced
hypertension, maternal anaemia and venous thromboem-
bolism.1 Compared to singleton newborns, newborn infants
of twin pregnancies are also at increased risk of adverse
outcomes including congenital anomalies, cerebral palsy,
intrauterine growth restriction and stillbirth. Although only
3% of all live births are twin pregnancies,1 twin babies
account for up to 15% of special care unit admissions.2 A
2009 survey conducted by the UK charity the Twin and
Multiple Birth Association (TAMBA) found that in 44% of
all twins born to the 1298 mothers interviewed, at least
one baby entered special care.3
According to the 2014 MBRRACE-UK (Mothers and
Babies: Reducing Risk through Audits and Confidential
Enquiries across the UK) report,4 the perinatal mortality rate
in twins was three times higher than that of singleton
pregnancies.4 Much of this perinatal mortality is driven by
prematurity. In Scotland, 50% of twins are delivered preterm
(at fewer than 37 weeks of gestation), with around 20%
delivering before 34 weeks of gestation.5 Figures from the
USA are similar: a 12-fold higher preterm birth (PTB) rate of
56.6% was found in twins compared to 9.7% in singletons
(odds ratio [OR] 12.8, 95% confidence interval
[CI] 12.6–12.9).6
Despite attempts by the UK’s National Institute for Health
and Care Excellence (NICE) to reduce multiple pregnancy
with the universal use of single embryo transfer (SET) during
assisted reproduction technologies (ARTs),7 the UK twin
pregnancy rate remains high among women undergoing
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ART, with up to 24% of successful in vitro fertilisation (IVF)
procedures resulting in multiple pregnancy.1 As well as the
increased risk of perinatal morbidity and mortality, the
economic cost of healthcare provision for a twin baby is
significantly higher than for singletons, and is quoted to be
twice as high in the first 5 years.8
The James Lind Alliance (JLA) Preterm Birth Priority Setting
Partnership (PSP) has prioritised the following question as the
number one uncertainty in preterm birth: which interventions
are most effective in predicting or preventing PTB? The JLA
brings together clinicians, patients and carers to set research
priorities in several aspects of obstetrics and gynaecology,
including stillbirth and endometriosis.9
Aetiology
The aetiology of spontaneous PTB in multiple pregnancies is
likely to be multifactorial, different from singletons, and
remains largely unknown. Different proposed pathophysiology
mechanisms include intrauterine infection, cervical
insufficiency and increased uterine stretch/distension. There
is also increased secretion of mediators such as corticotrophin-
releasing hormone (CRH) from the larger placental mass, and
factors produced by the maturing fetal lung such as surfactant
protein-A, which stimulates myometrial contractility and may
contribute to preterm parturition.10
Twins are associated with a higher risk of obstetric
intervention and therefore iatrogenic PTB is higher.
Approximately one-third of all premature deliveries in
multiple pregnancies are medically indicated.11 This review
focuses on the prevention of spontaneous PTB
in twin pregnancies.
Prediction of preterm labour in multiple
pregnancy
Detailed descriptions of the methods of prediction of PTB in
multiple pregnancy are out of the scope of this review, but
the evidence surrounding the two most researched methods,
cervical length and fetal fibronectin, is summarised below.
Cervical length measurement
In asymptomatic women with a twin pregnancy
A 2010 meta-analysis of 16 cohort/cross-sectional studies
(n = 3213)12 showed that in asymptomatic women with
twins, a cervical length of <25 mm was associated with a 25%
risk of delivery before 28 weeks of gestation. This review also
found a cervical length of <20 mm at 20–24 weeks of
gestation to be associated with a 42.4% risk of birth before
32 weeks, and a 62% risk of birth before 34 weeks. A
subsequent systematic review13 upheld these findings and
concluded that in asymptomatic women with a twin
pregnancy, a cervical length measurement at 20–24 weeks
of gestation was a good predictor of spontaneous PTB.
A recent systematic review of 1024 women with twins14
assessed repeated measures of a change in cervical length as a
predictor of PTB, and found that the shortening of cervical
length over time had a low predictive accuracy for preterm
birth at fewer than 34 weeks of gestation.
The largest and most up-to-date individual patient data
(IPD) meta-analysis on the effect of gestational age and
cervical length measurements in the prediction of PTB in twin
pregnancies was published by Kindinger et al.15 in 2015
(n = 4409 twin pregnancies). The benefit of an IPD meta-
analysis is that it is a more robust method of combining and
easily comparing studies, easily allowing subgroup analysis; for
example, a short cervix group. This analysis consisted of
12 twin cohorts and found that when cervical length was
<30 mm at 18 weeks of gestation, it was most predictive of
birth at ≤28 weeks. Prediction of later spontaneous PTB (28–
34 weeks) improved with cervical length measurements taken
at later gestations (≥22 weeks). The authors concluded by
recommending cervical length screening in twin pregnancies as
a predictor of spontaneous PTB from 18 weeks of gestation.
In summary, in asymptomatic women with a twin
pregnancy, current evidence supports the use of measuring
cervical length from 18 weeks of gestation as a predictor of
spontaneous PTB, but does not support repeated measures
of cervical length.
In symptomatic women with a twin pregnancy
In a meta-analysis of five combined cohort/cross-sectional
studies (n = 310), Conde-Agudelo et al.12 showed that, in
women with twin pregnancies and symptoms of spontaneous
PTB, cervical length measurement had a low predictive
accuracy for PTB at <34 weeks of gestation. However, the
review concluded that the sample size was small and there is a
paucity of evidence in the area of predicting PTB
in twin pregnancies.
Fetal fibronectin
In asymptomatic women with a twin pregnancy
NICE does not recommend the use of fetal fibronectin (fFN)
in multiple pregnancies. A 2010 meta-analysis16 summarising
11 studies of fFN use in asymptomatic twin pregnancy to
predict PTB suggested only limited prediction accuracy, and
better negative predictive rates than positive (6% risk of PTB
before 34 weeks of gestation with a negative test compared to
a 33% risk of PTB before 34 weeks with a positive test).
In symptomatic women with a twin pregnancy
The meta-analysis by Conde-Agudelo et al.16 synthesised the
results of five studies using fFN to predict PTB in
symptomatic women with a twin pregnancy. The authors
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concluded that fFN testing in multiple pregnancy was most
accurate in women with symptoms of PTB (positive and
negative likelihood ratios 85% and 75%, respectively, within
7 days of testing). However, although fFN testing is
recommended for use in singleton pregnancies with
symptoms of PTB if cervical length measurement is not
available,17 it is not recommended in the NICE guideline
for multiple pregnancy.
A combination of cervical length measurements and fFN
may be a more accurate predictor of PTB. One small study18
(n = 155 twin pregnancies) reported that if fFN was positive
and cervical length was <20 mm, then 54.4% of twins would
deliver before 34 weeks of gestation, and this was
significantly higher than the overall rate of PTB.
Methods of preterm birth prevention
Cervical cerclage
Cervical cerclage is a surgical technique to prevent PTB and
has been described in the UK literature since 1902.19
Although cerclage is endorsed by NICE for use in singleton
pregnancies, it is not recommended for use in multiple
pregnancy as its effectiveness remains controversial.11 A
subgroup of twins (n = 49 women) in a 2005 meta-
analysis20 investigating the use of cerclage showed an
increase in prematurity and a trend towards harm. In
multiple pregnancies, cerclage was associated with an
increased risk of premature delivery (relative risk
[RR] 2.15, 95% CI 1.15–4.01) and a trend towards an
increased risk of perinatal mortality. However, this finding
was not statistically significant, with wide confidence
intervals likely reflecting the small sample size (RR 2.66,
95% CI 0.83–8.54).
A subsequent Cochrane review published in 201421
examined five trials, of which two (n = 73 women) assessed
history-indicated cerclage and three (n = 55 women) assessed
ultrasound-indicated cerclage. This review found no benefit of
cervical cerclage in reducing preterm delivery in twin
pregnancies at fewer than 34 weeks of gestation (RR 1.16,
95% CI 0.44–3.36, four trials, n = 98 women). It also showed
a trend towards harm with an increased risk of perinatal death,
although this was not statistically significant (RR 1.74,
95% CI 0.92–3.28). There was no reduction in a composite
of adverse neonatal outcome (RR 1.54, 95% CI 0.58–4.11). In
the pre-specified subgroup, ultrasound-indicated cerclage was
associated with an increased risk of low birthweight (RR 1.39,
95% CI 1.06–1.83, three trials, n = 98 women) and
respiratory distress syndrome (RR 5.07, 95% CI 1.75–14.70,
three trials, n = 98 women). The authors concluded that there
was no evidence of the usefulness of cerclage in reducing the
risk of PTB in twins, but thatmore researchwas needed because
of a small number of trials, which each had a small number of
patients. It is also important to note that no trials were
identified that reported long-term infant neurodevelopmental
outcomes following cervical cerclage.
Ultrasound-indicated cerclage in twin pregnancies
Following the Cochrane review, a further IPD meta-analysis
was published looking specifically at ultrasound-indicated
cerclage (cervical length ≤25 mm before 24 weeks of
gestation) in twin pregnancies.22 Three randomised
controlled trials (RCTs; n = 49 women) were identified. No
significant differences in PTB rates before 34 weeks of
gestation were found between cerclage and no cerclage in
twin pregnancies with a trend towards harm (RR 2.19,
95% CI 0.72–6.63). Similar to the Cochrane review, the
authors concluded that further large trials were necessary to
determine the effectiveness of cerclage in twin pregnancies.
The latest retrospective cohort study was published in 2015
and involved 140 women with twin pregnancies.23 This
showed that ultrasound-indicated cerclage with a cervical
length of ≤25 mm did not reduce the risk of preterm delivery
before 34 weeks of gestation (adjusted OR [aOR] 0.37,
95% CI 0.16–1.1) nor was it associated with increased
neonatal morbidity (aOR 0.7, 95% CI 0.4–1.2). In the pre-
specified subgroup analysis of women with a cervical length
of ≤15 mm (n = 32 women), there was a significant
reduction in the rate of PTB before 34 weeks of gestation
(OR 0.42, 95% CI 0.24–0.81).
In summary, unlike singleton pregnancies, there appears to
be no benefit of cervical cerclage in reducing PTB rates in
multiple pregnancies. Although the study by Roman et al.22
reported a benefit in those with a short cervix (≤15 mm), the
numbers in the study were small and further large trials are
needed to address this question adequately.
A search on ClinicalTrials.gov identified two currently
recruiting studies comparing ultrasound and emergency
cerclage in twin pregnancies with expectant
management.24,25 One trial24 is a multicentre, international
RCT of physical exam-indicated cerclage in twin gestations
with a primary outcome measure of preterm delivery at fewer
than 34 weeks of gestation. The other study25 is a single-centre
RCT of cervical cerclage versus expectant management for
women with a twin pregnancy and a short cervix (≤25 mm),
with a primary outcome of pregnancy prolongation. The
‘C-STICH’ RCT26 of monofilament versus braided sutures for
insufficient cervix is currently recruiting in multiple centres in
the UK. Although this study only looks at singleton
pregnancies, a similar trial in twin pregnancies would be
appropriate after the results are published.
Progesterone
Is it biologically plausible?
The use of progesterone in the prevention of PTB in both
singleton and multiple pregnancies has been extensively
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investigated. Arguably, the use of progesterone is biologically
plausible given that uterine quiescence is maintained
throughout pregnancy by progesterone and progesterone
receptor-mediated inhibition of inflammation, which causes
suppression of the contractile genes.27 Labour is thought to
occur as a result of a functional withdrawal of progesterone.28
Anti-progesterones such as mifepristone are used to stimulate
abortion and induce labour. However, others have argued
that progesterone levels are high during pregnancy, and
progesterone receptors are fully occupied, hence the
therapeutic benefit of adding further progesterone is
unclear. Progesterone is available as an intramuscular
injection of 17a-hydroxylase caproate (only licensed in the
USA), or vaginal progesterone (the only available
progesterone product in the UK, but not licensed for
prevention of PTB in the USA or Europe).
Use of progesterone in unselected twin pregnancies
A 2012 IPD meta-analysis by Romero et al.,27 which
investigated the use of vaginal progesterone in singletons,
also included a subgroup of women with twins
(n = 52 women). This revealed no reduction in PTB before
34 weeks of gestation when vaginal progesterone was used in
twin pregnancies (RR 0.7, 95% CI 0.34–1.44). A subsequent
IPD meta-analysis by Schuit et al. (2015)29 upheld these main
conclusions. The review included 13 trials (3768 pregnancies)
of the use of progestogens in unselected twin pregnancies and
the primary outcome was neonatal morbidity. Treatment with
vaginal progesterone did not reduce the risk of adverse
perinatal outcome (RR 0.97, 95% CI 0.77–1.2), and there
were no significant differences for delivery before 32 weeks of
gestation between the progesterone and the control groups (RR
0.91, 95% CI 0.68–1.2).29
A recent systematic review and meta-analysis comparing
progesterone, cerclage and the cervical pessary for prevention
of PTB in unselected twin pregnancies found no reduction in
PTB rates with any of the interventions.30 Some secondary
outcomes were reduced with vaginal progesterone only (very
low birth weight, [RR 0.71, 95% CI 0.52–0.98], and need for
mechanical ventilation, [RR 0.61, 95% CI 0.45–0.82]).
One of the larger RCTs in the Schuit et al.29 IPD meta-
analysis, the ‘STOPPIT’ study (n = 500 women),31 performed
a baby follow-up study of the effect of prophylactic
progesterone in twin pregnancy on childhood outcome.32
Performed through record linkage of childhood records, this
study found no increased incidence of perinatal death
(15 twins in the progesterone group versus 11 in the
placebo group), congenital anomalies (OR 1.04, 95% CI
0.49–1.21) or hospitalisation (OR 0.97, 95% CI 0.71–1.33) of
those exposed to progesterone versus placebo. The authors
concluded there was no evidence of a detrimental or
beneficial impact on health and developmental outcomes at
3 and 6 years of exposure to progesterone in utero.
Use of progesterone in twin pregnancies in women with a
short cervix
Debate still exists as to whether progesterone is effective in
singleton pregnancies of women with a short cervix. The
Schuit et al.29 IPD meta-analysis published in 2015 included
a subgroup analysis of women with a twin pregnancy and a
short cervix of ≤25 mm (n = 116 women). Among this
subgroup, vaginal progesterone provided a protective effect
over the control with regards to adverse perinatal outcome
(RR 0.57, 95% CI 0.47–0.70). However, the number of
women in the subgroup was small, thus limited conclusions
can be inferred. The primary outcome in this study was
neonatal morbidity, therefore differences in PTB in the
subgroup of women with a short cervix ≤25 mm were not
investigated in this review.
In summary, there is no benefit of universal vaginal
progesterone to reduce PTB rates in multiple pregnancies.
One meta-analysis showed a benefit in adverse perinatal
outcome in a subgroup of women with a short cervix
≤25 mm, suggesting it may be useful in this group, but the
numbers in the study were small and further research is
needed. There appears to be no long-term harm caused to
infants exposed to progesterone in utero.32 The NICE
guidelines for multiple pregnancy currently followed by UK
practitioners do not promote the routine use of cervical
cerclage or progesterone for the prevention of PTB in
multiple pregnancies (see Box 1).
Cervical pessary
The Arabin pessary is a cervical pessary used to prevent PTB.
It is a flexible silicon ring with a smaller inner diameter that
encompasses the cervix, aiming to tilt it posteriorly and
provide cervical support.33 It is usually inserted at around
18–22 weeks of gestation, and in twin pregnancies is removed
before 36 weeks. The Arabin cervical pessary and its correct
positioning are shown in Figure 1. Available evidence
surrounding the use of the cervical pessary in twin
pregnancies is conflicting and is discussed here in terms of
unselected twin pregnancies and twins in women with
a short cervix.
Box 1. Preterm birth prevention in multiple pregnancy from the
National Institute for Health and Care Excellence guideline 20111
Do not use the following interventions (alone or in combination)
routinely to prevent spontaneous preterm birth in twin or triplet
pregnancies:
 Bed rest at home or in hospital
 Intramuscular or vaginal progesterone
 Cervical cerclage
 Oral tocolytics
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Use of the cervical pessary in unselected twin pregnancies
Two RCTs looking at the use of the cervical pessary in
unselected twin pregnancies have been performed. The
largest, by Nicolaides et al.34, which involved 1180 women
who received a cervical pessary versus expectant
management, found no difference in the rate of PTB before
34 weeks of gestation (RR 1.05, 95% CI 0.79–1.41).
The ProTWIN study35 was an RCT of 808 unselected twin
pregnancies. This study found no difference in PTB before
32 weeks of gestation (10% versus 12%, RR 0.86,
95% CI 0.65–1.15) and no reduction in adverse perinatal
outcome (RR 0.98, 95% CI 0.69–1.39).
Use of the cervical pessary in twin pregnancies with a
short cervix
The PECEP-Twins trial,36 published in 2016, is the only RCT to
focus on twins in women with a short cervix (defined as
≤25 mm). In this study, 137 women with a short cervix were
randomly assigned to cervical pessary or expectant
management groups. The rate of PTB before 34 weeks of
gestation was reduced in the pessary group compared with the
expectant management group (RR 0.41, 95% CI 0.22–0.76).
In a post hoc subgroup analysis of the study by Nicolaides
et al.,34 the incidence of PTB before 34 weeks of gestation
among 106 women with a cervical length of <25 mm was not
significantly different between the pessary group and the
expectant management group (31% versus 26%, RR 1.2,
95% CI 0.8–1.8). In contrast, subgroup analysis of the
ProTWIN study,35 which used a cervical length cut-off of
<38 mm, reported a reduction in PTB before 32 weeks of
gestation (16.2% versus 39.4%; RR 0.41, 95% CI 0.22–0.76).
In a systematic review and meta-analysis, Saccone et al.37
combined the results of the three trials of cervical pessary use
for the prevention of PTB of twins of women with a short
cervical length, and a forest plot was produced (Figure 2). It
is important to note here that because the Nicolaides et al.
and ProTWIN studies used different cervical length cut-offs
(<25 mm and <38 mm, respectively), they were not directly
comparable in the meta-analysis and therefore were not
powered to detect a difference in PTB in these subgroups.
The review concluded that use of the Arabin pessary in twin
pregnancies of women with a short cervix may not prevent
PTB or improve perinatal outcome.
In summary, evidence for the use of the cervical pessary for
the prevention of PTB in twins is conflicting, though there is
some evidence to suggest it may be useful in twin pregnancies
of women with a short cervix. The STOPPIT 2 RCT38 is
currently recruiting in the UK to help address this paucity of
evidence. This RCT aims to resolve the uncertainty
surrounding whether or not the Arabin pessary reduces
spontaneous PTB in twins of women with a short cervix
(<30th centile, which equates to 35 mm15). The cervical
pessary is not currently routinely used in clinical practice
outside of the research setting.
(a) (b)
Figure 1. a) The Arabin cervical pessary; b) the position of the Arabin cervical pessary.
Figure 2. Risk of preterm birth <34 weeks of gestation in twin pregnancies with a cervical length <25 mm.37
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Other methods of preterm birth prevention
As stated in Box 1, the following methods of PTB prevention
in multiple pregnancies are not endorsed by NICE. The
evidence is summarised below:
Bed rest and uterine monitoring
In the past, bed rest was used as a method of PTB prevention
for both singleton and twin pregnancies. A 2010 Cochrane
review39 comparing hospitalisation and bed rest against
expectant management summarised the results of six trials
(n = 600 women). It found no benefit of this intervention,
but did find an increased risk of PTB before 34 weeks of
gestation (OR 1.84, 95% CI 1.01–3.34). Similarly, a
1995 meta-analysis40 of six trials on the use of home
uterine monitoring showed no reduction in PTB. Thus,
neither of these interventions have been endorsed by NICE.
Prophylactic tocolytics
For singleton pregnancies, the RCOG’s Green-top
Guideline41 (GTG) supports the use of tocolysis for the
completion of corticosteroids or an in utero transfer, but not
for PTB prevention. Similarly, for multiple pregnancy, the
GTG states that there is insufficient evidence for its use in the
prevention of preterm labour. A 2005 Cochrane review42 of
five trials (n = 344 women) found no reduction in PTB
before 34 weeks of gestation with the use of tocolytics
(RR 0.47, 95% CI 0.15–1.50).
In summary, the use of prophylactic tocolytics to prevent
preterm labour in multiple pregnancy is not recommended.
Conclusion
There is a lack of effective, evidence-based interventions for
the prevention of PTB in twin pregnancies. There is limited
evidence for the use of vaginal progesterone and cervical
cerclage, and the cervical pessary is currently only used within
a research setting. There are no reported trials comparing the
effectiveness of each of these interventions against each other,
whether in isolation or in combination.43 Likewise, although
fFN and cervical length scanning may be beneficial in
predicting PTB in twins either alone or in combination, no
reliable evidence supports the use of any one predictor.
Research is needed to further evaluate the benefit of the
cervical pessary and the use of cervical cerclage in twins of
women with a short cervix. A recent article by Stock et al.43
concludes by advising clinicians to share with women the
uncertainty of methods to prevent PTB in multiple
pregnancy, and offer the opportunity to participate
in clinical trials.
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